Teva Pharmaceutical Industries Ltd (TEVA) Earnings: An Early Look

Page 1 of 2

Earnings season is in full swing, with huge numbers of companies having already given their latest numbers to investors. The key to making smart investment decisions with stocks releasing their quarterly reports is to anticipate how they’ll do before they announce results, leaving you fully prepared to respond quickly to whatever inevitable surprises arise. That way, you’ll be less likely to make an uninformed kneejerk reaction to news that turns out to be exactly the wrong move.

Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA)Let’s turn to Teva Pharmaceutical Industries Ltd (NYSE:TEVA) . The drug company has a unique balance, profiting from generics on one hand yet having its own proprietary drugs on the other. Let’s take an early look at what’s been happening with Teva Pharmaceutical over the past quarter and what we’re likely to see in its quarterly report on Thursday.

Stats on Teva Pharmaceutical

Analyst EPS Estimate $1.33
Change from Year-Ago EPS (16%)
Revenue Estimate $5.26 billion
Change from Year-Ago Revenue (7.4%)
Earnings Beats in Past 4 Quarters 3

Source: Yahoo! Finance.

Will Teva Pharmaceutical stay healthy?
Analysts have been pretty certain about their estimates for Teva Pharmaceutical in the just-concluded quarter, but over the past three months, they’ve pulled in their estimates for the first quarter and full-year 2013 sharply. The stock has been equally pessimistic, falling almost 8% since early November.

Teva is best known for its generic versions of off-patent drugs. Given how much less expensive generic versions are compared to their branded equivalents, health-care advocates argue that they’re essential to keeping drug costs down, even though they also discourage innovation. Teva hasn’t been content to stick with generics solely, though, also working on branded drugs. Its blockbuster drug is Copaxone, which is a treatment for multiple sclerosis.

For Copaxone, though, competition is on the horizon. Teva filed what’s known as a citizen’s petition with the FDA to try to delay approval of Biogen Idec Inc. (NASDAQ:BIIB)‘s BG-12 treatment for MS, which will go up directly against Copaxone if approved.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

10 Cities with High Demand for Nurses

6 of the Worst Greeting Card Messages Ever Crafted

6 Ways to Make Money in ArcheAge and Build Your Empire

10 Foods To Eat To Lower Cholesterol Levels

The 10 Most Hated Television Characters of All Time

The 30 Worst Halloween Costume Ideas Ever Brought to Horrible Life

10 Vocational Skills in Demand Today with Jobs Waiting to be Filled

10 Best Places to Visit in Central and South America

The 10 Greatest Empires in History Which Nearly Conquered the World

The 6 Cheapest Boarding Schools In America 2015

5 Clear Reasons LoL is Better than DotA, Continues to Rule MOBAs

The Only 9 Teams with a Chance to Win the Super Bowl

The 15 Most Common Phobias in America that Induce Fits of Panic

Top 6 Least Expensive Tourist Destinations in 2014

Jim Goetz, Peter Fenton, Jim Breyer: Top 6 Venture Investors for 2014

Top 15 Billionaires in 2014

5 Pitfalls To Avoid When Buying a Franchise

Top 20 Medical Schools in the US – 2014 Rankings

4 Business Strategies that Turned Jamie Oliver into the World’s Richest Chef

6 Qualities That Make You A Good Team Player

10 High Paying Seasonal Jobs in America this Holiday Season

The 10 Busiest Shipping Lanes in the World

5 Most Valuable Brands in China

The 10 States with Highest Substance Abuse Rates Crippling Their Populace

The Top 10 Things to Do Before You Die That Will Echo for Eternity

The 10 Best Selling Items on Etsy

Top 10 Things to Do in Tokyo, the Greatest City in the World

10 Mistakes on Social Media that Can Harm You and Will Probably Get You Canned

The 10 Best Cities to Find Jobs in 2014

The 10 Most Controversial Songs Of All Time to Hit (and get Banned from) the Airwaves

The 20 Biggest IPOs in US History

The 10 Best Places to Visit in Mexico that Are Beautiful and Safe

7 Bad Habits that Age You Beyond Your Years

The 40 Best Fortune Cookie Sayings That Will Leave You Bemused, Befuddled, or Beguiled

10 Foods to Eat Before a Workout to Make Every Drop of Sweat Count

The 5 Best Documentaries On Netflix You Must See

The Most Heartwarming and Inspirational Story Of This Halloween Season, It Will Make You Cry and Jump For Joy

10 Best Party Songs of All Time to Bring the House Down With

5 New World Order Conspiracy Theories that Will Strangle the World

The 10 Highest Rated Movies of 2014

The 10 Largest Container Shipping Companies in the World

The 10 Largest Armies in the World: Who Should We Be Afraid Of?

Best Warren Buffett Quotes on Money You Need to Hear

The 10 Highest Suicide Rates by Profession

The 20 Most Underrated Movies of All Time

The 10 Fastest Growing Companies in America

The 10 Biggest Outlet Malls in USA

The 5 Most Popular Rap Songs of All Time

The 10 Countries that Eat the Most Meat

The10 Most Expensive Countries to Fly To

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!